M. Bella

发表

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

A. Musolino, M. Capelletti, A. Ardizzoni, 2007, Breast.

The changing distribution and survival of colorectal carcinoma: an epidemiological study in an area of northern Italy

L. Sarli, M. Bella, M. Michiara, 2005, European journal of gastroenterology & hepatology.

Early Detection of Recurrences in the Follow-up of Primary Breast Cancer in an Asymptomatic or Symptomatic Phase

A. Musolino, G. Cocconi, S. Cascinu, 2004, Tumori.

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

A. Marchetti, F. Buttitta, M. Fassan, 2022, ESMO open.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories

A. Marchetti, F. Buttitta, P. Radice, 2019, Diagnostics.

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.

D. Amadori, M. Marangolo, M. Tonato, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

M. Tonato, F. Roila, G. Tognoni, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin

M. Maltoni, D. Amadori, G. Luporini, 1999 .

Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.

F. di Costanzo, G. Cocconi, V. Malavasi, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bcl‐2 expression on fine‐needle aspirates from primary breast carcinoma

G. Cocconi, R. Camisa, M. Bella, 1999, Cancer.

Brca Status, Molecular Profile and Clinical Variables in Primary Bilateral Breast Cancers: A Population-Based Cancer Registry Study

A. Musolino, A. Ardizzoni, R. Camisa, 2012 .

Aminoglutethimide in Advanced Breast Cancer

G. Cocconi, R. Passalacqua, M. Bella, 1985, Tumori.

Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.

M. Marangolo, M. Tonato, F. Roila, 1990, Clinical oncology (Royal College of Radiologists (Great Britain)).

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.

C. Boni, M. Tonato, G. Cocconi, 1992, The New England journal of medicine.

Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.

A. Musolino, R. Camisa, C. Pinto, 2016, Acta bio-medica : Atenei Parmensis.

Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study

A. Musolino, M. Capelletti, A. Ardizzoni, 2005, Tumori.

Vinorelbine combined with paclitaxel infused over 96 hours (VI‐TA‐96) for patients with metastatic breast carcinoma

G. Cocconi, M. Bella, F. Ferrozzi, 2000, Cancer.

Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH).

G. Cocconi, R. Passalacqua, M. Bella, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.

F Leonardi, C Finardi, G. Cocconi, 1999, American journal of clinical oncology.

Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.

F. di Costanzo, G. Cocconi, M. Bella, 1999, American journal of clinical oncology.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

A. Marchetti, P. Radice, P. Tassone, 2016, Future oncology.

Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes.

C. Boni, P. Bruzzi, G. Cocconi, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A regional population‐based hereditary breast cancer screening tool in Italy: First 5‐year results

D. Santini, A. Perrone, L. Cortesi, 2020, Cancer medicine.

A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes

A. Musolino, M. Capelletti, A. Ardizzoni, 2005, Breast Cancer Research and Treatment.

Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma

C. Boni, P. Bruzzi, G. Cocconi, 2002, Cancer.

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.

F. di Costanzo, M. Soldani, G. Cocconi, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

A. Marchetti, F. Buttitta, P. Radice, 2019, Critical reviews in oncology/hematology.

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel

C. Marchetti, E. Maccaroni, F. Martella, 2020, Supportive Care in Cancer.

Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.

A. Musolino, A. Ardizzoni, M. Bella, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

F. di Costanzo, P. Carlini, M. Bella, 1996, American journal of clinical oncology.

Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E=Epirubicin, V=Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma

C. Boni, M. Tonato, F. Costanzo, 2011 .

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

A. Marchetti, P. Radice, P. Tassone, 2016, Future oncology.